NICE has recommended that Akcea’s hereditary transthyretin-related amyloidosis (hATTR) treatment Tegsedi be made available on the NHS in England, ahead of a rival therapy from Alnylam.
The latest crop of financings in the digital health category includes a sizeable $84 million round for Wellvana Health, with Genialis, ThoughtFull, and Mindset Health also
